Share Name Share Symbol Market Type Share ISIN Share Description
Akers Biosciences, Inc LSE:AKR London Ordinary Share US00973E1029 COM SHS NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 76.50p 68.00p 85.00p 76.50p 76.50p 76.50p 0 07:56:12
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 2.4 -2.7 -49.4 - 6.79

Akers Biosciences Share Discussion Threads

Showing 3951 to 3970 of 3975 messages
Chat Pages: 159  158  157  156  155  154  153  152  151  150  149  148  Older
DateSubjectAuthorDiscuss
16/10/2017
09:47
Top work John "Release The Hounds" Gormally: In connection with the exercise of the Original Warrants, the Company will issue an additional warrant to each Exercising Holder for the number of shares of Common Stock equal to one hundred percent of the number of exercised shares purchased by such Exercising Holder, with an exercise price of $1.26 per share. The Additional Warrants will be substantially identical to the Original Warrants, except that the exercise price of the Additional Warrant is $1.26 and such warrant is not exercisable for six months after issuance. hTtps://marketexclusive.com/akers-biosciences-inc-nasdaqaker-files-an-8-k-entry-into-a-material-definitive-agreement-3/2017/10/
mcmather
14/10/2017
20:32
SUMMARY - Q2 2017 Conference call (15 August 2017); John Gormally et al Akers campaign towards profitability continued in Q2 2017.... Chlamydia 510K submission completed. Commenced production to fulfil First Check order; very excited. $1.2m in cash and marketable securities 30 June 2017. HIT awareness programme laying groundwork for continued profitable growth. Oxi Check - Exceptionally exciting initiatives. We believe it will be a major driver of profitable growth in the future. HIT - Acurity; fairly significant inroads with the hospitals on Puerto Rico but not at the point of claiming victory on conversion. Walt - First Check, supplying end of this quarter; prove that I said something completely different on 11 April 2017? Oh, it was recorded was it, ahh right. Is it Friday yet Johnny Boy, let's get in that war room! Release The Hounds - First Check order will result in an 'intial bump' - no, not that Walt, get down we're still live in the call - with smaller but recurring revenues thereafter with the product in the stores before year end. Oxi Check - one company is actively investigating our offer...ripest opportunity. By next conference call confident of solidifying that relationship and generating revenue. China (Novotek; the JV company) - believe that they are now at the end of the road re "product pricing approval" hence their order. Also developed a more basic device (ie cheaper) for the more rural areas. Novotek has spent $m's seeding(?) the market - Eh, no Walt, that on Friday is a different kind of seeding. Apparently 90 hospitals ready to order once approval in place. Novotek also "globalising"; ie they now have a plant in Poland and which apparently opens that market (eastern Europe) in October 2017. Walt - just provided additional data to FDA re 510K for Chlamydia. In response to a question re just a bit better than 2 quarters of cash on the balance sheet, "yes, that's a fair statement"..... Transcript here: hTtps://seekingalpha.com/article/4099110-akers-biosciences-aker-ceo-john-gormally-q2-2017-results-earnings-call-transcript
mcmather
14/10/2017
18:53
SUMMARY - 2016 results Conference call (11 April 2017); John Gormally et al A turnaround year for our firm. 85% sales increase in our flagship PIFA Heparin (HIT) Successfully implemented evidence based value proposition; ie increased the price of the product by circa 85%. HIT sales in the US are growing steadily. Sales force focused on Integrated Delivery Networks (IDNs). BIG WIN December 2016; purchasing award with GNYHA (now Acurity). 3 year agreement. Powerful level of access. Concurrently developing other business opportunities (HIT) in Western Europe. 10 April 2017 the Acurity agreement extends in to Puerto Rico. Initial order for Tri-Cholesterol with First Check. Oxi Check - more of an impact this (2017). Working ahead our strategic plan anticipates further profitable growth (HIT). Dr Walt; We aim to launch into the market Chlamydia & Ketotis. Chlamydia "will be on the market early Q3 2017. Oxi-Check introduced last year and JG have put a strategy in place. First Check (Tri-Cholesterol) "shipping this quarter(Q2 2017)". JG - not anticipating any more financing this year cough cough splutter; just ignore any RNSs 13 Oct 2017. Walt - Chlamydia will be cleared early 3rd quarter 2017; JG and his team are putting together cunning plans. JG - re HIT / Acurity / Puerto Rico; "we call it internally here release the hounds", Mr John 'Release The Hounds' Gormally. Purchase Order for First Check "will happen in Q2 2017". Gary Rauch re-iterates cash burn target is $80k-$82.5k or $6.2m revenue. Chlamydia tests will generate $9.50 per test.
mcmather
13/10/2017
14:53
A reminder of what was said in the Q3 conference call 14 Nov 2016: $613k revenue / up 262% on Q3 2015 / no significant revenue from China / essentially revenue related to US sales of PIFA Heparin (HIT). The quarter was 'net profitable' due to a $1.3m accounting reversal of a bad debt. John J Gormally (JG) said the untapped potential of HIT was the key attractor in him joining Akers. That and the massive wage unrelated to performance. Winner! (That last bit obviously wasn't in the conference call) US sales of HIT "growing steadily". I had to stop typing for a bit after that one!! In addition to Cardinal Health and Fisher Health, their own sales force were now targeting Integrated Delivery Networks (IDNs). Indeed, the adaption of their PIFA awareness campaign and this new strategy was now beginning to take shape. They had presented to regional health care systems and to their senior management and with their offering here said to have "resonated well" with them to the extent that no IDNs appear to have come on board as of the latest results in 2017! Both JG and Gary Rauch alluded to the fulfilment of the shipment of the order to China before year end with JG suggesting that revenue would equal US sales of the device. They must surely have known that there was no chuffin chance of that at that time; see the posts on here re the subsequent placings. They had their first paying customer for the Oxi-Check device. This was said to be validation of their efforts for the previous 18 months. It will be interesting to see how sales for this product have fared in the 12 months since. Cash burn for Q3 2016 was $88.3K per week. Annual revenue of $4.6m would equate to their being cash neutral; which does not seem right? Q4 2016 EXPECTED to be profitable. Nice one Johnny! Also, they are on track to be profitable across next year. Nice one son! In closing - ie due to there being questions asked of them - JG said that they "remained very confident.....they HAVE turned the corner.....profitability within our grasp near term..... really promising future....Big Wally what's 311,000 divided by 52 again?!?"
mcmather
12/10/2017
21:51
Interesting rise and not displeasing.
algernon2
12/10/2017
15:32
Looks technical as far as I can make out from the posts on this US site: hTtps://stocktwits.com/symbol/AKER
mcmather
12/10/2017
15:25
Hmmm - what was that on nasdaq?
mcmather
11/10/2017
23:35
Just a bit concerned that John J Gormally is the same as Dr Mitty and so started to review his performance here / what he has said / what has come to fruition / what has not / etc. John J Gormally has been on board for approaching 2 years now; appointed CEO 23 November 2015. He's very well remunerated - $311,025 apparently: hTtp://www.biospace.com/News/velano-vascular-adds-medical-device-industry/470778 He's also on the Advisory Board of an enterprise called Velano Vascular and whose initial aim, via funding / investment, appears to be to "draw blood more efficiently from patients" via their PIVO device: hTtp://velanovascular.com/people/ Q3 results are not for another month yet but so far Gormally has seen unit sales of Aker's flagship product, PIFA Heparin, reduce in their main US market in his 2 years on board. Earning $300k per annum. Folk who are good with numbers would appear to go to Harvard University.
mcmather
11/10/2017
22:38
The stated 'target' for AKR is said to be a cash burn of $80k-$82.5K per week. At 30 June 2017 (H1 2017) they had "cash and marketable securities totaling $1,208,800" with cash at 30 June 2017 of $197,175. Slightly surprisingly there have been no additional filings of late with the SEC re possible additional placings? hTtp://www.nasdaq.com/symbol/aker/sec-filings
mcmather
09/10/2017
22:58
IS there anybody there?' said the Traveller, Knocking on the moonlit door; And his horse in the silence champed the grasses Of the forest's ferny floor. And a bird flew up out of the turret, Above the Traveller's head: And he smote upon the door again a second time; 'Is there anybody there?' he said. But no one descended to the Traveller; No head from the leaf-fringed sill Leaned over and looked into his grey eyes, Where he stood perplexed and still. But only a host of phantom listeners That dwelt in the lone house then Stood listening in the quiet of the moonlight To that voice from the world of men: Stood thronging the faint moonbeams on the dark stair, That goes down to the empty hall, Hearkening in an air stirred and shaken By the lonely Traveller's call. And he felt in his heart their strangeness, Their stillness answering his cry, While his horse moved, cropping the dark turf, 'Neath the starred and leafy sky; For he suddenly smote on the door, even Louder, and lifted his head:— 'Tell them I came, and no one answered, That I kept my word,' he said. Never the least stir made the listeners, Though every word he spake Fell echoing through the shadowiness of the still house From the one man left awake: Ay, they heard his foot upon the stirrup, And the sound of iron on stone, And how the silence surged softly backward, When the plunging hoofs were gone.
algernon2
29/9/2017
13:43
CHU CHU THE TRAIN. Ever travelling, never gets there
norbus
27/9/2017
09:54
Another one lost whilst Walt has had his left thumb up his hoop with his right hand counting. In Development: Rapid Breath Test for Troponin™ A single-use, non-invasive, breath-based diagnostic device to rapidly screen for Troponin, which can be indicative of myocardial infarction (MI), commonly referred to as a heart attack. If approved, this developmental test will provide results in minutes using MPC® Biosensor Technology. No capital equipment or specialized training is required. hTtp://www.akersbio.com/products/tests-in-development/troponin-myocardial-infarction 27 Sept 2017 - 'Instant' blood test for heart attacks. hTtp://www.bbc.co.uk/news/health-41399159
mcmather
26/9/2017
16:20
Gormless seems to be as bad as Walt #TheFlyingDeuces
mcmather
26/9/2017
14:17
What a mouth watering short CFD; I Can't indulge; I do not short.
norbus
20/9/2017
09:11
MCM NOW, IF YOU ONLY KNEW THAT 90 WAS SHREWD BUYING AT THE BOTTOM.
norbus
16/9/2017
00:52
They are ramping up their PR on twitter; this doesn't appear to be doing any good though at the moment based upon the latest results. hTtps://twitter.com/akersbio?lang=en&;lang=en&lang=en hTtps://twitter.com/AkersWellness?lang=en
mcmather
18/8/2017
21:04
https://www.youtube.com/watch?v=WtLB930dIV4
algernon2
14/8/2017
11:53
Maybe, maybe not - Walt is very dangerous from a shareholder's perspective.
mcmather
14/8/2017
10:18
20p spread online and somebody sells for 65p when 70-90p that is unbelievable !
love it
13/8/2017
11:11
love it, that's in the header (ie there for all to see) - and the rise is from an all time low?
mcmather
Chat Pages: 159  158  157  156  155  154  153  152  151  150  149  148  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20171019 07:21:37